Risk-benefit assessment of ivabradine in the treatment of chronic heart failure

References

• McMurrayJJAdamopoulosSAnkerSDESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESCEur Heart J2012148803869
   Web of Science ®Google Scholar
• DyerARPerskyVStamlerJHeart rate as a prognostic factor for coronary heart disease and mortality: findings in three Chicago epidemiologic studiesAm J Epidemiol198011267367497457467
   PubMed Web of Science ®Google Scholar
• KannelWBCupplesLAHeart rate and cardiovascular mortality: the Framingham studyAm Heart J19871136148914943591616
   PubMed Web of Science ®Google Scholar
• SwedbergKKomajdaMBöhmMIvabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled studyLancet2010376974487588520801500
   PubMed Web of Science ®Google Scholar
• FoxKFordIStegPGTenderaMRobertsonMFerrariRIvabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomized, double-blind, placebo-controlled trialLancet2008372964180781618757088
   PubMed Web of Science ®Google Scholar
• ThollonCCambarratCVianJProstJFPeglionJLVilaineJPElectrophysiological effects of S16257, a novel sino-atrial node modulator, on rabbit and guinea-pig cardiac preparations: comparison with UL-FS 49Br J Pharmacol1994112137428032660
   PubMed Web of Science ®Google Scholar
• SulfiSTimmisADIvabradine – the first selective sinus node I(f) channel inhibitor in the treatment of stable anginaInt J Clin Pract200660222222816451297
   PubMed Web of Science ®Google Scholar
• TardifJCFordITenderaMBourassaMGFoxKEfficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable anginaEur Heart J200526232529253616214830
   PubMed Web of Science ®Google Scholar
• LevineHJRest heart rate and life expectancyJ Am Coll Cardiol1997304110411069316546
   PubMed Web of Science ®Google Scholar
• CustodisFSchirmerSHBaumhäkelMHeuschGBöhmMLaufsUVascular pathophysiology in response to increased heart rateJ Am Coll Cardiol201056241973198321126638
   PubMed Web of Science ®Google Scholar
• HeuschGHeart rate in the pathophysiology of coronary blood flow and myocardial ischaemia: benefit from selective bradycardic agentsBr J Pharmacol200815381589160118223669
   PubMed Web of Science ®Google Scholar
• FoxKFordIStegGTenderaMRobertsonMFerrariRRelationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trialEur Heart J200930192337234519720635
   PubMed Web of Science ®Google Scholar
• HeuschGA BEAUTIFUL lesson – ivabradine protects from ischaemia, but not from heart failure: through heart rate reduction or more?Eur Heart J200930192300230119720636
   PubMed Web of Science ®Google Scholar
• BöhmMSwedbergKKomajdaMHR as a risk factor in chronic heart failure (SHIFT): the association between HR and outcomes in a randomised placebo-controlled trialLancet2010376974488689420801495
   PubMed Web of Science ®Google Scholar
• StilesSSHIFT: adding HR-slowing agent ivabradine to HF meds cuts mortality, hospitalizationMedscape2012332228132820 Available from: http://www.medscape.com/viewarticle/790694Accessed March 12, 2014
   Google Scholar
• BorerJSBöhmMFordIEffect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT studyEur Heart J201233222813282022927555
   PubMed Web of Science ®Google Scholar
• SwedbergKKomajdaMBöhmMEffects on outcomes of HR reduction by ivabradine in patients with CHF: is there an influence of beta-blocker dose? Findings from the SHIFT studyJ Am Coll Cardiol201259221938194522617188
   PubMed Web of Science ®Google Scholar
• KomajdaMBöhmMBorerJInfluence of background treatment with mineralocorticoid receptor antagonists on ivabradine’s effects in patients with chronic heart failureEur J Heart Fail2013151798422892123
   PubMed Web of Science ®Google Scholar
• BagriyAEShchukinaEVMalovichkoSIEarly addition of ivabradine shortens carvedilol uptitration and improves exercise capacity in patients with chronic heart failureEuropean Journal of Heart Failure201315S1S140
   Google Scholar
• KramerDGTrikalinosTAKentDMAntonopoulosGVKonstamMAUdelsonJEQuantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approachJ Am Coll Cardiol201056539240620650361
   PubMed Web of Science ®Google Scholar
• TardifJCO’MearaEKomajdaMEffects of selective HR reduction with Ivabradine on left ventricular remodeling and function: results from the SHIFT echocardiography substudyEur Heart J201132202507251521875858
   PubMed Web of Science ®Google Scholar
• SarulloFMFazioGPuccioDImpact of “off-label” use of ivabradine on exercise capacity, gas exchange, functional class, quality of life and neurohormonal modulation in patients with ischemic chronic heart failureJ Cardiovasc Pharmacol Ther201015434935520940450
   PubMed Web of Science ®Google Scholar
• KomajdaMNovel approaches to HR modulation in chronic heart failureKardiol Pol2013716549551 Polish23797425
   PubMed Web of Science ®Google Scholar
• BorerJSBohmMFordIEfficacy and safety of ivabradine in patients with severe chronic systolic heart failure/left ventricular dysfunction in the SHIFT trialEur J Heart Fail20141133497503
   Google Scholar
• TavazziLSwedbergKKomajdaMEfficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT studyEur J Heart Fail201315111296130323803951
   PubMed Web of Science ®Google Scholar
• MajewskiSSlomkaSZielinska-WyderkiewiczECiebieadaMGorskiPHeart rate-lowering efficacy and respiratory safety of ivabradine in patients with obstructive airway diseaseAm J Cardiovasc Drugs201212317918822409211
   PubMed Web of Science ®Google Scholar
• GreenCPPorterCBBresnahanDRSpertusJADevelopment and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failureJ Am Coll Cardiol20003551245125510758967
   PubMed Web of Science ®Google Scholar
• BelardinelliRGeorgiouDCianciGPurcaroARandomized controlled trial of long-term moderate exercise training in chronic heart failure. Effect on functional capacity, quality of life, and clinical outcomeCirculation19999991173118210069785
   PubMed Web of Science ®Google Scholar
• HuboSHGollubSBuorgeRBeneficial effect of pimobendan on exercise tolerance and quality of life in patients with heart failure: results of a multicenter trialCirculation19928539429491537130
   PubMed Web of Science ®Google Scholar
• DaubertJCSaxonLAdamsonPB2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and managementEuropace20121491236128622930717
   PubMed Web of Science ®Google Scholar
• MaggioniAPAnkerSDDahlstrőmUAre hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12440 patients of the ESC Heart Failure Long-Term RegistryEur J Heart Fail201315101173118423978433
   PubMed Web of Science ®Google Scholar